ATAGI 关于 6 个月至 4 岁儿童使用辉瑞 COVID-19 疫苗的建议
ATAGI 现已推荐辉瑞 COVID-19 疫苗用于部分 6 个月至 5 岁的儿童（Moderna <5 COVID-19 疫苗已被推荐用于该组）。符合条件的人群包括那些免疫功能严重受损的人、有严重或复杂健康需求的残疾者，或者患有多种/复杂健康状况会增加患严重 COVID-19 疾病风险的人。
建议采用主要的三剂量方案，间隔 8 周，剂量为 3mcg。与 Moderna 在该年龄组的主要接种计划不同，建议所有符合条件的 5 岁以下儿童接种 3 剂，无论其免疫状况如何。
这个年龄组没有品牌偏好，但 ATAGI 建议使用相同的疫苗完成初级计划。
基于一系列因素，ATAGI 目前不建议不属于上述类别的 6 个月至 5 岁儿童接种 COVID 疫苗。
随着替代品牌或变体 COVID-19 疫苗在这个年龄段可用，或者如果出现流行病学变化（例如出现新的令人担忧的变体），建议可能会发生变化。
要完整阅读 ATAGI 声明，请点击以下链接：
ATAGI 关于 6 个月至 4 岁儿童使用辉瑞 COVID-19 疫苗的建议
ATAGI 在 2022 年 11 月 11 日举行的 COVID-19 会议后更新了助推器
鉴于澳大利亚 COVID-19 病例数量的增加以及 Omicron 亚变体 XBB 和 BQ.1 的出现，ATAGI 提供了加强建议的最新信息。
虽然没有提供额外剂量的新建议，但 ATAGI 重申了与当前推荐剂量保持同步的重要性。疫苗接种不足的人因 COVID-19 而患重病和死亡的风险仍然增加。
最近的数据（截至 2022 年 11 月 9 日）显示，550 万符合条件的人尚未接受第一剂加强剂。此外，还有 320 万 50 岁或以上的人没有接受第二剂加强剂。
如果您现在应该接受加强剂量，您可以通过 COVID-19 疫苗诊所查找器.
要完整阅读 ATAGI 更新，请参阅以下链接：
ATAGI 在 2022 年 11 月 11 日举行的 COVID-19 会议后更新了助推器
ATAGI 关于使用辉瑞二价（原版/Omicron BA.1）COVID-19 疫苗的建议
ATAGI 在最近获得 TGA 临时批准后，提供了使用辉瑞二价 COVID 疫苗的建议。这意味着现在有 2 种二价 COVID 疫苗可供澳大利亚使用——Moderna 和辉瑞。
辉瑞二价疫苗含有等量的来自原始 SARS-CoV-2 病毒和 Omicron BA.1 变体刺突蛋白的 mRNA。
ATAGI 建议任何年满 18 岁或以上且有资格获得加强剂量的人都可以接种辉瑞二价疫苗。不建议在 COVID 疫苗接种的初级课程中使用。
没有偏好品牌的二价或原始 mRNA COVID 疫苗作为加强剂量。
如需完整阅读 ATAGI 建议，请访问以下链接：
ATAGI 关于使用辉瑞二价药物的建议 （原创/Omicron BA.1）COVID-19 疫苗
ATAGI 关于 5 至 11 岁儿童接种辉瑞 COVID-19 儿科疫苗加强剂量的建议
ATAGI have recommended COVID-19 booster doses for some groups of 5-11 year olds who have previously completed a primary course of COVID-19 vaccination. Eligible groups include those with severe immunocompromise, a disability with significant or complex health needs, or those with complex/multiple health conditions that increase the risk of severe COVID-19 disease.
Boosters in this age group can be administered 3 or more months after completing a primary course of COVID-19 vaccines. An interval of 3 months between COVID-19 infection and COVID vaccines is recommended.
There is currently not enough evidence to support booster doses for other groups of 5-11 year olds, however recommendations may change as more evidence emerges. All children in this age group are recommended to receive a primary course of COVID-19 vaccination.
To read the recommendations in full please follow the link below.
AusVaxSafety 提供世界首个 JYNNEOS 猴痘疫苗的实时安全数据
新发布的 AusVaxSafety 对 1,300 多剂 JYNNEOS® 首剂疫苗的监测数据显示，54% 疫苗接种者在疫苗接种后的前 7 天内没有出现任何副作用。在报告症状的疫苗接种者中，副作用通常是轻微且短暂的，包括局部反应、疲劳、头痛和肌肉/关节疼痛。
为了提供有关在澳大利亚使用 JYNNEOS® 的进一步指导，AusVaxSafety 将继续收集和发布这些信息，包括第 2 剂后的副作用。
要阅读完整更新，请单击下面的链接。
全球首个 JYNNEOS 猴痘疫苗的实时安全数据可从 AusVax安全
ATAGI 关于 12-17 岁青少年使用 Novavax 疫苗的建议
ATAGI have now recommended that adolescents aged 12-17 years can receive the Novavax COVID-19 vaccine for their primary course of COVID-19 vaccination. This recommendation provides another vaccine brand option, in addition to Pfizer and Moderna, for individuals in this age group.
A Novavax primary schedule consists of 2 doses, administered 8 weeks apart. Those with 严重的免疫功能低下 should receive 3 doses.
Whilst Novavax is not currently registered for use as a booster dose in adolescents aged 12-17 years, ATAGI advises that it may be used for this purpose, when Pfizer is not suitable for that person.
To read the recommendations in full please follow the link below.
ATAGI recommendations on the use of the Novavax vaccine for adolescents aged 12-17 years.
疫苗工作 GAVI：过去和现在有关猴痘的五张图表
Despite the first cases of monkeypox infection in humans being reported in the 1970’s, previous outbreaks of disease have been relatively small compared with the international outbreak we are currently experiencing. Human to human transmission has been historically uncommon with cases limited to smaller geographical regions. Current rates of infection, with extensive human to human transmission and wide global spread has led this outbreak to be a very unique scenario.
The following article uses the latest data to explore the current rates of infection across different demographics and regions, the impact of pre-existing medical conditions, as well as vaccine access and severity of disease.
To read the article in full, click on the link below.
疫苗工作 GAVI：过去和现在有关猴痘的五张图表
To view our reference page on monkeypox, click on the link below.
MVEC：猴痘
VACSIG 网络研讨会录音现已提供
A webinar recording is now available from the recent Vaccination Special Interest Group (VACSIG) event on Wednesday 17 August. The topic for the webinar was Monkeypox & smallpox vaccines: an Australian perspective, and featured a panel of expert speakers including MVEC’s A/Prof Nigel Crawford.
To view the recording, please click on the link below.
VACSIG Webinar 17 August
ATAGI 关于 5 岁以下儿童使用 COVID-19 疫苗的建议
ATAGI have now recommended COVID-19 vaccination for some children aged 6 months – 5 years. Eligible groups include those with severe immunocompromise, a disability with severe or complex health needs, or those with multiple/complex health conditions that increase the risk of severe COVID-19 disease.
A paediatric formula of the Moderna COVID-19 vaccine has been approved by the TGA in this age group for children in the groups mentioned above. A primary two-dose schedule, 8 weeks apart is recommended, with the dose being 25mcg. Children in this age group with severe immunocompromise are recommended to complete a 3-dose primary schedule.
基于一系列因素，ATAGI 目前不建议不属于上述类别的 6 个月至 5 岁儿童接种 COVID 疫苗。
随着替代品牌或变体 COVID-19 疫苗在这个年龄段可用，或者如果出现流行病学变化（例如出现新的令人担忧的变体），建议可能会发生变化。
To read the recommendations in full please follow the link below.
ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years